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Objectives. This study sought to establish the effect of amiloride 
on stunned myocardium and to determine the role of hemo- 
dynamic alterations and inhibition of sodium/proton (Na+/H +) 
exchange and e-type cytosolic calcium (Ca 2+) channels. 
Background. Amiloride is a nonspecific agent that may reduce 
reperfusion injury, but its effect on reversible dysfunction or 
stunned myocardium is unclear. 
Methods. Ninety-seven open chest dogs undergoing 15 min of 
left anterior descending coronary artery occlusion and 3 h of 
reperfusion with monitoring of hemodynamic variables, systolic 
shortening and myocardial blood flow were randomized to seven 
intracoronary infusions: control dogs (5% dextrose, n = 16); low 
dose amiloride (1 mg/min, n = 14); high dose amiloride 
(5 mg/min) with (n = 12) and without (n = 16) atrial pacing; 
sodium nitroprusside (20 t~g/min, n = 16); hexamethylene amilo- 
ride (a specific inhibitor of Na +/H + exchange, 60 p.g/min, n = 14); 
and nifedipine (a specific inhibitor of e-type Ca a+ channels, 5 
/~g/min, n = 9). Drug infusions were started 40 rain before 
occlusion and stopped at 30 min after reperfusion. 
Results. Forty-three dogs were excluded because of ventricular 
fibrillation or high collateral flow. The incidence of ventricular 
fibrillation was similar in all groups to that in control dogs. 
Systolic shortening completely recovered (p = NS vs. baseline; 
p < 0.01 vs. control group) by 2 h after reperfusion in the low dose 
amiloride group and 30 rain in the high dose group (p < 0.01 vs. 
low dose). High dose amiloride increased myocardial blood flow 
and had positive inotropie and negative chronotropie ffects (p < 
0.05 vs. control group). Atrial pacing did not attenuate recovery. 
The only effect of low dose amiloride was increased myocardial 
blood flow after reperfusion. Systolic shortening did not deterio- 
rate after washout of drug effects. Sodium nitroprusside and 
nifedipine similarly increased myocardial blood flow, but systolic 
shortening never recovered. Hexamethylene amiloride had no 
hemodynamic effects, and systolic shortening never recovered. 
Conclusions. Amiloride prevented the contractile dysfunction of 
myocardial stunning but did not prevent arrhythmias. Hemody- 
namic alterations, increased myocardial blood flow and inhibition 
of Na+/H + exchange or t-type Ca 2+ channels alone did not 
account for the improved function. Inhibition of Na+/Ca z+ ex- 
change may be the mechanism of improved postischemic function. 
(JAm Coil Cardio11995;26:1365-73) 
One of the causes of reversible postischemic contractile dys- 
function of stunned myocardium ay be increased cytosolic 
calcium (Ca 2+) (1-7). Sodium (Na+)/Ca > exchange may 
mediate the increase in cytosolic Ca 2+ because ischemia nd 
reperfusion increase intracellular Na" (1,7). Inhibition of 
Na+/potassium (K +) adenosine triphosphatase (ATPase), 
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nonspecific leak or activation of Na+/H + (proton) exchange 
may mediate the increase in Na + (8). 
Amiloride is a nonspecific agent that has been shown to 
reduce postischemic dysfunction due to irreversible injury in 
isolated hearts (9-14). Perfusion with 100 to 1,000/,mol/liter 
amiloride before and after global ischemia improved postisch- 
emic function by reducing the infarct size. Its effect on 
postischemic dysfunction due to reversible injury is unclear 
(15). 
Amiloride may improve the postischemic contractile dys- 
function of stunned myocardium by reducing Na + or Ca 2+ 
overload. Amiloride may prevent Na* overload by inhibiting 
Na+/H + exchange (effective concentration -100 txmol/liter) 
or voltage-gated Na + channels (-600 txmol/liter) (9,10). 
Amiloride may directly minimize Ca 2+ overload by inhibiting 
~.-type Ca > channels (-100 b~mol/liter) or Na+/Ca 2+ ex- 
change (-1,000 ~mol/liter) (9,10,16). Amiloride may also 
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reverse the contractile dysfunction by altering hemodynamic 
variables during occlusion or after reperfusion (13,17-24). 
We hypothesized that amiloride would reduce the contrac- 
tile dysfunction of stunned myocardium by direct inhibition of 
Na+/Ca 2+ exchange. Severe, reversible, regional postischemic 
dysfunction without infarction was produced by 15-rain occlu- 
sion of the proximal eft anterior descending coronary artery 
and 3 h of reperfusion. Agents were infused intracoronary to
minimize hemodynamic alterations. Our objectives were to 
determine the roles of 1) positive inotropy; 2) increased 
myocardial blood flow and reduced arterial pressure (25); 3) 
negative chronotropy; 4) inhibition of L-type Ca 2+ channels 
(24,26); 5) inhibition of Na+/H + exchange; and 6) inhibition of 
Na+/Ca z+ exchange (14,27). Inhibitors of Na + channels do not 
improve postischemic function (28). Other inhibitors of Na+/ 
Ca 2 + exchange (benzamil and bepridil) are limited by the same 
nonspecific effects as amiloride (29). 
Methods 
General preparation. Mongrel dogs (15 to 30 kg) were 
anesthetized with intravenous sodium pentobarbital (15 mg/kg 
body weight) and barbital (300 mg/kg) and ventilated. Saline 
solution (0.9%) was infused at 300 ml/min, and body temper- 
ature and arterial blood gases were maintained atphysiologic 
levels. Arterial and left ventricular pressures were measured by 
a high fidelity double-tipped pressure catheter (Millar PC 771 ) 
inserted from the left carotid artery. Left ventricular pressure 
was electronically differentiated on-line. Silastic atheters were 
inserted in the right femoral artery and vein. 
A thoracotomy was performed in the left fifth intercostal 
space and the heart suspended in a pericardial cradle. A 
segment of the left anterior descending coronary artery was 
isolated proximal to the first major diagonal branch. A cali- 
brated electromagnetic flow probe (Statham SP7515) and a silk 
ligature were placed around the artery. A small branch distal to 
the ligature was isolated and cannulated retrogradely with a 
heparin-filled 27-gauge silastic atheter (PE-60). The catheter 
tip was advanced into the left anterior descending coronau' 
artery, and its position was confirmed by injection of food 
coloring. A Silastic catheter was inserted in the left atrial 
appendage for microsphere injection. 
All dogs received humane care according to the "Principles 
of Laboratory Animal Care" by the National Society for 
Medical Research and the "Guiding Principles for Research 
Involving Animals and Human Beings" (U.S. Department of 
Health and Human Services, NIH Publication No. 8623, 
revised 1985). 
Regional myocardial function. After identification of the 
distributions of the left anterior descending (ischemic zone) 
and left circumflex coronary arteries (nonischemic zone), pairs 
of 5.0-MHz sonomicrometers were implanted in the subendo- 
cardium in both zones in the circumferential p ane of the left 
ventricle. Segment length was continuously monitored by 
ultrasound transit ime (Triton. model 120) (30). End-diastole 
was the onset of rapid increase in left ventricular pressure. 
IC Drug/Saline Infusion Washout Period 
Time -40 0 15 45 195 min 
i Ii i 
Occ Reperfusion 
Microspheres  ^ ^ ^ ^ 
Figure 1. Experimental protocol. The protocol consisted ofa 45-rain 
pretreatment period, 15 min of left anterior descending coronary 
artery occlusion (Occ) and 3 h of reperfusion. I tracoronary (IC) 
infusion of drug or vehicle into the ischemic zone was started 40 rain 
before occlusion (-40 min), continued throughout occlusion (0 to 
15 min) and stopped after 30 rain of reperfusion (15 to 45 rnin). The 
total drug infusion period was 85 min (-40 to 45 min). The washout 
period was 150 rain (45 to 195 rain). Regional myocardial blood flow 
(Microspheres) was assessed 10 rain before occlusion (-10 min), 
l0 rain after occlusion (10 min) and 30 min (45 rain) and 3 h after 
reperfusion (195 rain). 
End-systole was peak negative derivative of left ventricular 
pressure (dP/dt) (30). Systolic shortening (SS) was the percent 
change in segment length from end-diastole (EDL) to end- 
systole (ESL): SS = [(EDL - ESL)/EDL] x 100. 
Regional myocardial blood flow. Regional myocardial 
blood flow was measured by the radiolabeled microsphere 
technique at (Fig. 1): 1) 10 mix before occlusion; 2) 10 mix 
alter occlusion; 3) 30 mix after reperfusion; and 4) 3 h after 
reperfusion (31). Carbonized plastic microspheres (cerium-41, 
chromium-51, rubidium-103 or niobium-95, 15 _+ 2 /xm in 
diameter [mean + SD]; New England Nuclear) in 10% dextran 
and 0.01% Tween 80 were ultrasonicated (Branson Electron- 
ics) for 5 mix and then vortexed (Scientific Industries) for 5 
more mix. Twenty microcuries (3 to 4 x 106 microspheres) was 
injected into the left atrium. Reference blood samples were 
collected from the right femoral artery at 7 ml/min for 130 s 
just before microsphere injection. 
At the end of each experiment, the left anterior descending 
coronary artery was occluded and India ink injected to delin- 
eate the area at risk. The heart was electrically fibrillated, 
removed and fixed in 10% formalin. Ischemic and nonischemic 
zones were separated and weighed. Tissue samples (0.8 to 
1.0 g) from the central ischemic (five samples) and nonisch- 
emic (three samples) regions were divided into subendocar- 
dial, midmyocardial nd subepicardial layers and weighed. Net 
activity of each isotope in tissue and reference blood samples 
was measured by a gamma counter (Packard Series 5000) and 
IBM-compatible software. Tissue blood flow was calculated by: 
Qm = (Qr × Cr/Cm) X 100, where Qm = tissue blood flow 
(ml/min/100 g); Qr = withdrawal rate of reference blood flow 
sample; C r = reference blood sample activity (cpm); and Cm = 
tissue sample activity (cpm). Blood flows were the mean value 
of all samples in each territory. Dogs with ischemic zone 
subendocardial blood flow >0.20 ml/min per gram during 
occlusion were excluded (32). 
Sham studies. Dose-response studies with intracoronary 
amiloride (0 to 10 rag/mix), nifedipine (0 to 50 /~g/min), 
sodium nitroprusside (0 to 80 /zg/min) and hexamethylene 
amiloride (0 to 120 tzg/min) were performed in six dogs. For 
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amiloride, 1 mg/min was the maximal dose with no effect on 
myocardial blood flow or contraction; and 5 rag/rain had 
positive inotropic and negative chronotropic effects and in- 
creased myocardial blood flow. For nifedipine, 5 ~g/min was 
the maximal dose that increased myocardial blood flow alone. 
Higher doses progressively reduced regional systolic shorten- 
ing. For sodium nitroprusside, 20 txg/min was the maximal dose 
that produced coronary vasodilation without hypotcnsion. For 
hexamethylene amiloride, 60 /xg/min was the maximal dose 
with no effect on blood flow, hemodynamic variables or 
myocardial contraction. A dose of 120 p~g/min creased blood 
flow and had a positive inotropic effect. 
Experimental protocol. Dogs were randomized to seven 
treatment groups: 1) control (5% dextrose); 2) low dose 
amiioride (100 mg in 100 ml of 5% dextrose; 1mg/min); 3) high 
dose amiloride (500 mg in 100 ml of 5% dextrose; 5 mg/min); 
4) sodium nitroprusside (2 mg in 100 ml 5% dextrose; 
20/xg/min); 5) hexamethylene amiloride (6 mg in 100 ml 5% 
dextrose with 3% dimethylsulfoxide; 60 ~g/min); 6) nifedipine 
(1 mg in 200 ml 5% dextrose with 1% ethanol and 0.5% 
polyethylene glycol 400; 5 p~g/min); and 7) high dose amiloride 
plus pacing and dimethylsulfoxide. The latter group was paced 
at the baseline heart rate by a bipolar electrode clamped to the 
left atrial appendage (Grass SMD9B stimulator). 
After surgical instrumentation and initial measurements 
(hemodynamic variables, coronary flow and segment shorten- 
ing), intracoronary drug or vehicle infusion was started at 
1 ml/min (Fig. 1). The coronary artery was occluded 40 min 
later. Measurements were recorded (Grass polygraph) at 1, 2, 
5, 10 and 15 rain. The silk ligature was released after 15 min of 
occlusion. Intracoronary infusion was stopped at 30 min fol- 
lowed by a 150-min washout period. Measurements were 
recorded at l, 2, 5, ll/, 20, 30, 60, 90, 120, 150 and 180 min. If 
ventricular fibrillation occurred, dogs were defibrillated with 
internal pads on the high lateral left ventricle and the right 
ventricle with up to three shocks (20, 3(I and 30 J). Preliminary 
studies revealed no prolonged effects on ischemic or nonisch- 
emic zone function. 
Statistical analysis. All reported values are expressed as 
mean value _ SE. Repeated measures and one-way analysis of 
variance with the Bonferroni t test were used to identify 
changes in continuous data within each group and between 
groups, respectively (33). Chi-square analysis was used to 
evaluate the effects of animal exclusion for lethal ventricular 
arrhythmias or high collateral blood flow during occlusion. A 
two-tailed p < 0.05 was considered significant. 
Resul ts  
Animal data. Ninety-seven dogs were randomized. Ven- 
tricular fibrillation occurred in 56 dogs (58%), and 39 (40%) 
were refractory to defibrillation. None of the 20 dogs that 
fibrillated during occlusion survived, but 17 (47%) of the 36 
that fibrillated after reperfusion survived. Ventricular fibrilla- 
tion occurred in 8 (50%) of 16 control dogs; 1 (11%) of 9 
nifedipine-treated dogs; 9 (64%) of 14 low dose amiloride- 
treated ogs; 8 (50%) of 16 sodium nitroprusside-treated dogs; 
13 (81%) of 16 (p = 0.10 vs. control) high dose amiloride- 
treated dogs; 10 (83%) of 12 dogs treated with high dose 
amiloride, pacing and dimethylsulfoxide; and 7 (50%) of 14 
hexamethylene amiloride-treated dogs. Defibrillation was suc- 
cessful in one control dog; four low dose amiloride-treated 
dogs; two sodium nitroprusside-treated dogs; five high dose 
amiloride-treated dogs; four dogs treated with high dose 
amiloride, pacing and dimethylsulfoxide; and one hexamethyl- 
ene amiloride-treated dog. Four dogs were excluded for high 
collateral blood flow to the ischemic zone during coronary 
occlusion, including one control dog, one low dose amiloride- 
treated og, and two sodium nitroprusside-treated dogs (p = 
NS). The final groups included eight each in the control, 
nifedipine, low dose amiloride, sodium nitroprusside, high 
dose amiloride, and hexamethylene amiloride groups and six in 
the high dose amiloride with atrial pacing and dimethylsulfox- 
ide group. 
Hemodynamic variables. Hemodynamic data are summa- 
rized in Figure 2. Low dose amiloride, hexamethylene amilo- 
ride and nifedipine did not alter hemodynamic variables. High 
dose amiloride reduced heart rate and rate-pressure product 
without altering mean arterial pressure. Sodium nitroprusside 
reduced mean arterial pressure and rate-pressure product 
without changing heart rate. Atrial pacing resolved systemic 
hemodynamic differences in dogs treated with high dose 
amiloride. 
Coronary occlusion did not alter hemodynamic variables in 
any group, but drug-induced ifferences persisted. Peak posi- 
tive dP/dt was higher in dogs treated with sodium nitroprusside 
and high dose amiloride and lower in dogs treated with 
hexamethylene amiloride. 
After repeffusion, hemodynamic-induced differences per- 
sisted during drug infusion. All hemodynamic alterations re- 
solved after stopping drug infusion, indicating that drug effects 
washed out. Heart rate in dogs treated with high dose amilo- 
ride without atrial pacing increased to values imilar to those at 
baseline at 3 h after repeffusion but remained lower than those 
in control dogs. 
Myocardial blood flow. Myocardial blood flow in isehemie 
and nonischemic zones is summarized in Table 1. During 
pretreatment, low dose amiioride and hexamethylene amilo- 
ride did not alter blood flow. High dose amiloride and nifed- 
ipine increased blood flow in the ischemic zone only. Sodium 
nitroprusside similarly increased blood flow in the ischemie 
zone but also increased blood flow in the nonischemic zone, 
which was indicative of spillover of drug effects into the 
systemic irculation. 
lschemic zone blood flow markedly decreased uring cor- 
onary occlusion in all groups. Ischemic zone blood flow was 
lowest in the subendocardium in all groups. 
After reperfusion, alterations inblood flow persisted uring 
drug infusion. Blood flow to the ischemic zone was elevated in 
dogs treated with low dose amiloride, high dose amiloride, 
sodium nitroprusside and nifedipine. Blood flow, especially to 
the subendoeardium, was higher than that at pretreatment in 
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Figure 2. Heart rate, mean arterial pressure (MAP), rate-pressure 
product (RPP) and peak positive derivative ofleft ventricular p essure 
(+dP/dt) during the experimental protocol. A, Heart rate was reduced 
in high dose amiloride-treated dogs (HD AML [5 mg/min]) but 
remained similar to that in control dogs in all other groups. Heart rate 
in high dose amiloride-treated dogs increased tovalues similar to those 
at baseline during the washout period but remained lower than that in 
control dogs. B, Mean arterial pressure was altered only by sodium 
nitroprusside (SNP) and was lower in these dogs during drug infusion 
but recovered during the washout period. C, Rate-pressure product 
was similar to that in control dogs for all groups except those treated 
with high dose amiloride alone. Rate-pressure product in these 
experiments was lower than that in control dogs only during drug 
infusion. D, High dose amiloride and sodium nitroprusside increased 
peak positive dP/dt, which remained higher in high dose amiloride- 
treated and sodium nitroprusside-treated dogs than in control dogs 
during occlusion but was lower in hexamethylene amiloride (HMA)- 
treated ogs than in control dogs. All differences resolved uring the 
washout period. DMSO = dimethylsulfoxide; LD AML = low dose 
amiloride (1 mg/min); NIFED - nifcdipine: P = atrial pacing. *p < 
0.05 versus control dogs. 
low dose amiloride-treated dogs. Blood flow was not altered by 
hexamethylene amiloride. Atrial pacing and dimethylsulfoxide 
did not attenuate high blood flow in high dose amiloride- 
treated dogs. All differences resolved during the 150-min 
washout period. Blood flow to the ischemic zone was similar in 
all treatment groups at 3 h after reperfusion, indicative of 
washout of drug effects. The increased blood flow to the 
nonischemic zone produced by sodium nitroprusside persisted 
throughout the drug infusion but resolved uring the washout 
period. 
Area at risk. Left ventricular mass, ischemic zone mass and 
the area at risk were 106 _+ 4 g, 34 _+ 2 g and 32 _+ 2%, 
respectively, in control dogs. Left ventricular mass, ischemic 
zone mass and area at risk were similar in all groups, except for 
sodium nitroprusside-treated dogs in which both findings were 
smaller (p < 0.05) than in control dogs (27 -+ 3 g and 24 _+ 2%, 
respectively). 
Regional myocardial function. Low dose amiloride, nifed- 
ipine and hexamethylene amiloride did not alter systolic 
shortening during the pretreatment period (Fig. 3, A and B). 
High dose amiloride and sodium nitroprusside increased sys- 
tolic shortening inthe ischemic and nonischemic zones (Fig. 3, 
B and C). The increase in systolic shortening in high dose 
amiloride-treated dogs resulted from a direct positive inotropic 
effect because pacing and dimethylsulfoxide id not attenuate 
the increase, and afterload was not altered. In contrast, the 
increased systolic shortening in sodium nitroprusside-treated 
dogs resulted from reduced mean arterial pressure (Fig. 3, A 
and C). 
Coronary occlusion caused similar systolic lengthening in all 
treatment groups. After reperfusion, systolic shortening never 
improved in control dogs (Fig. 3, A). Low dose amiloride 
caused systolic shortening to gradually increase after reperfu- 
sion (Fig. 3, A). The recovery continued uring the washout 
period and was complete by 2 h after reperfusion (p = NS vs. 
baseline). High dose amiloride further accelerated the recov- 
ery of systolic shortening after reperfusion (Fig. 3, A). Systolic 
shortening completely recovered within the first 30 min (p < 
0.01 vs. the low dose amiloride group; p = NS vs. baseline) and 
did not deteriorate during the washout period. Pacing and 
dimethylsulfoxide id not attenuate he recovery in high dose 
amiloride-treated dogs (Fig. 3, A). Systolic shortening never 
recovered in dogs treated with sodium nitroprusside despite a 
similar increase in myocardial blood flow and reduced arterial 
pressure during drug infusion (Fig. 3, B). Systolic shortening 
partially recovered uring drug infusion but rapidly regressed 
to systolic lengthening during the washout period (p = NS vs. 
control). Likewise, systolic shortening never ecovered in dogs 
treated with the L-type Ca 2+ channel blocker nifedipine de- 
spite high myocardial blood flow during drug infusion (Fig. 3, 
B). The specific inhibitor of Na +/H + exchange, hexamethylene 
amiloride, failed to reproduce the results of low or high dose 
amiloride (Fig. 3, B). Systolic shortening in hexamethylene 
amiloride-treated dogs remained similar to that in control dogs 
throughout reperfusion. 
In the nonischemic zone, occlusion of the left anterior 
descending artery increased systolic shortening in all groups 
(Fig. 3, C). The increase in systolic shortening during occlusion 
was greatest in dogs treated with high dose amiloride and 
sodium nitroprusside. After reperfusion, systolic shortening 
returned to baseline in all groups. 
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Table 1. Regional Myocardial Blood Flow (ml/min per 100 g) in Ischemic and Nonischemic Zones 
Before 10 rain After 30 rain After 3 h After 
Occlusion Occlusion Reperfusion Reperfusion 
Nonischemic zone 
Transmural 
Control dogs 101 + 12 13(1 _+ 22 104 + 8 106 _+ 9 
LD AML 81 -+ 9 100 _~ 10 102 + 11 104 _+ 11 
HD AML 107 ± 7 102 _~ 8 103 z 13 91 -+ 9 
SNP 172 +_ 29* 213 _+ 33* 212 _+ 39* 120 _+ 16 
Nifedipine 121 ~_ 9 105 + 13 98 + 8 94 _+ 13 
HMA 83 -~ 8 90 + 7 99 _+ 12 99 _+ 7 
HD AML/P/DMSO 121! ± 8 130 + 8 128 _+ 12 120 _+ 10 
Endo/epi flow ratio 
Control dogs 1.111 _+ 0.13 0.97 ± 0.12 0.98 + 0.16 1.03 _+ 0.13 
LD AML 0.93 _+ 0.11 0.95 + 0.08 0.96 + 0.10 1.03 _+ 0.09 
HD AML 0.97 _+ 0.08 0.97 + 0.10 1.04 _+ 0.05 1.18 _+ 0.06 
SNP 0.85 + 0.06 0,87 + 0,05 0.81 _+ 0.05 0.95 _+ 0.15 
Nifedipine 1.00 + 0.12 1.13 + 0.15 1.04 + 0.14 1.19 _+ 0.09 
HMA 0.85 _~ 0.03 !1.89 ~ 0.05 0.86 _+ 0.07 0.81 _+ 0.05 
HD AML/qP/DMSO (I.99 +_ 0.09 11.96 -_ ()All 1.01 + 0.05 1.08 _+ 0.07 
Ischemic zone 
Subepicardium 
Control dogs 94 _+ 13 10 + 5+ 82 _+ 12 89 _+ 10 
LD AML 109 _+ 15 9 + 7t 168 _+ 15" 79 _+ 12 
HD AML 223 ± 27* 17 + 85. 299 _+ 35* 106 + 217 
SNP 256 + 35* 11 + 45. 251 _+ 35* 83 _+ 11"1" 
Nifedipine 246 ± 40* 8 + 2~ 177 _+ 27* 107 -+ 157 
HMA 87 ± 8 12 ± 6+ 77_+ 14 84_+ 12 
HD AML/P/DMSO 272 ± 30 ~ I0 ~ 6+ 305 ± 37* 110 -+ 197 
Subendocardium 
Control dogs 89 _~ 32 2 - 1~ 56 _+ 7 67 _+ 7 
LD AML 126 ~_ t] 2 7 1+ 265 - 25*? 87 _+ 10 
HD AML 223 -_ 27* 7 + 4t 373 ± 51' 106 _+ 217 
SNP 256 _~ 38* ~ _+ 35. 240 + 3l* 64 _+ 217 
Nifedipine 218 ± 27* 2 + I- 156 _+ 26* 77 _+ 127 
HMA 82 ± 9 t~ + 35 55 ± 7 77 _+ 8 
HD AMUP/DMSO 27(i ± 27* 3 _+ 35. 398 _+ 51' 111 _+ 2H 
Endo/epi flow ratio 
Control dogs 0.97 + 0.09 0.2(I + (1,10? 0.71 + 0.045 0.79 _+ 0.07 
LD AML 1.33 +~: 0,18 0.53 _+ (I,227 1.74 ± 0.28* 1.18 _+ 0.09* 
HD AML 1.07 2 (I.13 il.3(I + 0.20+ 1.29 + 0.16' 0.90 _+ 0.08 
SNP 1.03 ± 11.08 11.38 - 0.167 0.99 _+ 0.09 0.89 + 0.10 
Nifedipine 0,96 :~ 0,12 11,29 _" 0.1I? 0.91 ___ 0.08 0.71 + 0.09 
HMA 11.95 + 0.04 0,41 + 0.08? 0.76 ± 0.04 0.94 _+ 0.04 
HD AML/P/DMSO 1.01 _-t). 13 0,3(! + 0.20? 1.35 + 0.16" 1.02 -- 0.10 
*p < 0.05 versus control group, tp < 0.('~ versus preocclusion. Data presented are mean value _+ SE. DMSO = dimethylsulfoxide; Endo/epi = 
endocardial/cpicardial; HD AML = high dose amiloride (5 rag/rain); HMA = hexamethylcne amiloride; LD AML = low dose amiloride (1 rag/rain); P = atrial pacing; 
SNP = sodium nitroprusside. 
Discussion 
Previous studies. Previous studies (1,11-14) have shown 
that amiloride improves postischemic myocardial function in 
isolated rodent heart models of 12 to 60 min of zero-flow 
global ischemia and reperfusion or hypoxia and reoxygenation, 
but the mechanism is unclear. Tani et al. (11) reported that 200 
to 1,000 /zmol/liter amiloride increased postischemic devel- 
oped pressure and reduced diastolic pressure, myocardial Na ~ 
and Ca 2+ content after reperfusion. In contrast, Weiss et al. 
(12) reported that 1,000 txmol/liter amiloride had a ve~, 
negative inotropic effect and lowered intraceUular pH. Hearts 
tolerated only 100 /zmol/liter amiloride, but postischemic 
developed pressure was higher and diastolic pressure and Ca z+ 
content lower. The mechanism was not clear because amiloride 
reduced heart rate and Ca 2+ content during pretreatment, 
increased intracellular Na + during ischemia and accelerated 
recovery of intracellular Na + and pH after reperfusion. 
Karmazyn (13) reported that 174/~mol/liter amiloride during 
ischemia and reperfusion had no sustained protective effect in 
hearts subjected to 30 rain of ischemia and only modestly 
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Figure 3. Systolic shortening (SS) fl'om ischcmic (IZ) and nonischemic 
zones (NZ) in control dogs and dogs treated with low dose amiloride: 
high dose amiloride with atrial pacing and 3% dimethylsulfoxide; high 
dose amiloride alone; sodium nitroprussidc: hexamethylene amiloride: 
and nifedipine. During coronary occlusion, systolic lengthening in the 
ischemic zone was similar in all groups. A, Before occlusion, high dose 
amiloride increased systolic shortening in both ischemic and nonisch- 
emic zones. Pacing and dimethvlsulfoxide did not attenuate he 
increase in function. Low dose amiloride had no effect on systolic 
shortening. After reperfusion, systolic shortening in the ischemic zonc 
of control dogs never ecovered. Systolic shortening in dogs treated 
with low dose amiloride steadily increased throughout reperfusion a d 
completely recovered by' 2 h after onset of reperfusion. High dose 
amiloride accelerated the recovery of systolic shortening. Systolic 
shortening completely recovered within the first 30 rain. Pacing and 
dimethylsulfoxide didnot attenuate r covery. Systolic shortening did 
not regress after washout of either low or high dose amiloride. B, 
Systolic shortening in the ischemic zone never ecovered in dogs 
treated with sodium nitroprusside, hexamethylene amiloride or nifed- 
ipine. C, In the nonischemic zone, systolic shortening increased during 
coronary occlusion in all groups but decreased to baseline within 
60 min after reperfusion. *p < 0.05 versus control dogs. #p < 0.1)5 
versus high dose amiloride-treated dogs. Abbreviations a  in Figure 2. 
improved function and injury in hearts ubjected to 60 rain of 
ischemia. A study by Karmazyn et al. (14) demonstrated that 
amiloride was as effective as hexamethylene amiloride 
(1 p, mol/liter) and bcpridil (10/xmol/liter) inimproving postisch- 
emic function after zero-flow ischemia but was more effective 
after hypoxia. The data contradict the conclusion that inhibi- 
tion of Na+/l-I + and Na+/Ca > exchange accounts for amilo- 
ride's effect. Amiloride was more effective than hexamethylene 
amiloride; however, Na+/Ca 2+ exchange was not inhibited. 
None of the agents prevented Ca 2+ paradox-mediated dys- 
function. The concentrations of amiloride and bepridil were 
too low. Heart rate and myocardial contraction were not 
altered (17). 
The role of Na+/H + exchange inreperfusion i jury has also 
been studied with the inhibitor HOE 694 (34-37). Its potency 
is similar to dimethylamiloride and is 30 times greater than 
amiloride (37). Concentrations of 1 ~mol/liter are effective at 
50% of physiologic Na +, but efficacy at physiologic Na + has 
not been reported (37). Effects on Na+/Ca e+ exchange have 
not been studied, but HOE 694 has no effect on heart rate or 
myocardial contraction (17). Sack et al. (34) reported that 
HOE 694 improved postischemic systolic shortening from 
-5I)% to -70% of baseline in pigs subjected to two 10-rain 
occlusion and reperfusion (34). HOE 694 also prevented 
ventricular fibrillation and did not alter hemodynamic vari- 
ables. Myocardial blood flow was not measured. Hendrikx et 
al. (35) reported that 1/zmol/liter HOE 694 and 500/zmol/liter 
amiloride before occlusion and after reperfusion equally im- 
proved postischemic developed pressure in isolated rabbit 
hearts undergoing 45 rain of zero-flow global ischemia and 
reperfusion. Infarction was the major cause of postischemic 
dysfunction i the control group. Amiloride at 500/zmol/liter 
reduces heart rate, but its role was not investigated. "No 
reflow" occurred in the control group. Amiloride and HOE 
694 increased coronary blood flow throughout infusion and 
after eperfusion, respectively. The role of vasodilation was not 
studied. Neither study assessed postischemic function after 
drug washout. 
Kitakaze t al. (38) used acidic reperfusion i isolated ferret 
hearts undergoing zero-flow ischemia nd reperfusion to doc- 
ument a major role for Na+/Ca 2+ exchange in reperfusion 
injury. Acidic reperfusion or ammonium chloride pretreatment 
improved postischemic developed pressure, Ca 2+ responsive- 
ness and maximal Ca 2 +-activated pressure development. Both 
treatments produced a myocardial pH known to inhibit Na+/ 
Ca -~ and Na+/Ca 2+ exchange (39,40). 
Conclusions derived from isolated heart studies may not be 
valid in stunned myocardium, and all previous studies of 
amiloride used the isolated heart model. Postischemic dysfunc- 
tion mainly resulted from infarction, whereas the contractile 
dysfunction of stunned myocardium is totally reversible (2,15). 
Zero-flow ischemia abolished global function. Reduced post- 
ischemic developed pressure resulted from increased iastolic 
pressure. In vivo, severe postischemic contractile dysfunction 
can be produced that is completely reversible (2-5). Regional 
ischemia causes dyskinesia, but the heart continues to function. 
Systolic dysfunction persists for days, whereas diastolic func- 
tion recovers within hours (2-5). Postischemic Ca 2+ respon- 
siveness and maximal Ca2+-activated force are depressed in
isolated hearts, but stunned myocardium responds normally to 
extracellular Ca 2+ and inotropic agents (2,15). 
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Mechanism of amiloride. The present study documents 
that intracoronary amiloride prevents the contractile dysfunc- 
tion of stunned myocardium and that its nonspecific effects on 
heart rate, coronary flow and myocardial contraction have no 
independent role. High and low dose intracoronary amiloride 
normalizes postischemic systolic function within 30 min to 2 h 
after reperfusion. 
Amiloride inhibits L-type Ca 2 + channels, voltage-gated Na ~ 
channels and alpha- and beta-receptors at the same concen- 
trations inhibiting Na+/H ÷ and Na+/Ca > exchange 
(9,10,16,41,42). Positive inotropic effects may reverse postisch- 
emic dysfunction without preventing injury (18-20) but were 
not a factor because contractile function did not deteriorate 
after drug washout. Inhibition of alpha-adrenoceptors and 
vascular c-type Ca 2+ channels may reverse postiscbemic dys- 
function by the Gregg phenomenon (21) but was not a factor 
because increased myocardial blood flow by sodium nitroprus- 
side or nifedipine alone did not prevent myocardial stunning. 
Bradycardic agents like beta-adrenergic and L-type Ca 2+ chan- 
nel antagonists may improve postischemic function (22,23). 
Bradycardia was not a factor because pacing did not attenuate 
the improved function. Inhibition of myocardial L-type Ca z+ 
channels may prevent reperfusion i jury (24,43-45), but pos- 
itively inotropic effects indicated that these channels were not 
inhibited by amiloride. Finally, inhibitors of voltage-gated Na + 
channels do not prevent postischemic dysfunction (28). 
Inhibition of Na+/H ~ exchange alone also did not account 
for the improved postischemic function. Hexamethylene 
amiloride is the most potent inhibitor of Na+/H + exchange in 
the amiloride series (9,10) but did not improve postischemic 
function. Dose-response studies validated the finding that 
60/xg/min was the maximal dose without he nonspecific effects 
of increased blood flow and myocardial contraction (34-37). 
Estimated plasma concentrations were 10 to 100 times the 
minimal inhibiting concentration (0.1 to 0.2 /,mol/liter) (9). 
Dimethylsulfoxide did not impair postischemic function be- 
cause recovery in high dose amiloride dogs was not affected. 
Inhibition of Na+/Ca 2~ exchange may account for the 
prevention of myocardial stunning by amiloride. The positive 
inotropic and negative chronotropic effects of high dose amilo- 
ride are signs of inhibition of Na +/Ca 2 ~ exchange (17). Both 
low and high dose amiloride produced effective estimated 
plasma concentrations (1,000 to 4,000 ~mol/liter, espectively) 
during occlusion (9,10). Amiloride is highly permeable and 
minimally protein bound, so p[asma concentrations reflect 
myocardial concentrations (46). 
Effect on ventricular fibrillation. The Na+/H ~ exchange 
has been reported to contribute to reperfusion arrhythmias, 
and amiloride may reduce the incidence of reperfusion ven- 
tricular arrhythmias (35,47). Amiloride (10 to 50/~mol/liter), 
dimethylamiloride (I0 to 50 /,mol/liter) and hexamethylene 
amiloride (0.2 to 1.0/xmol/liter) equally reduced the incidence 
of reperfusion arrhythmias in isolated rodent hearts (47). The 
bradycardic effects of dimethylamiloride and hexamethylene 
amiloride may have contributed totheir antiarrhythmic effect. 
Amiloride's effect occurred at concentrations that do not 
inhibit Na+/H + exchange. HOE 694 also prevented reperfu- 
sion arrhythmias in pigs (35). 
The results of the present study demonstrate different 
results. The estimated concentrations of low and high dose 
amiloride and hexamethylene amiloride were higher than the 
minimal concentration for inhibiting Na+/H + exchange. High 
dose amiloride reduced heart rate and had positive inotropic 
effects consistent with inhibition of Na +/Ca 2+ exchange. Hexa- 
methylene amiloride and low dose amiloride had no effect on 
ventricular arrhythmias. High dose amiloride tended (p = 
0.10) to increase ventricular arrhythmias. These results implied 
that 1) the causes of arrhythmias in the present model differ 
from those in isolated hearts; 2) Na+/H + exchange is not an 
important mechanism of ischemic or reperfusion ventrieular 
arrhythmias; and 3) inhibition of Na+/Ca 2+ exchange may 
exacerbate ischemic or reperfusion arrhythmias. 
Study limitations. The mechanism by which amiloride 
prevented the contractile dysfunction of stunned myocardium 
was derived inferentially by the present study. There are no 
specific inhibitors of Na+/Ca 2+ exchange to corroborate this 
mechanism (29). Bepridil and benzamil also inhibit Na+/Ca 2+ 
exchange, but effective concentrations have the same nonspe- 
cific effects as amiloride (29). 
Myocardial Ca 2+ was not measured in the present study 
because techniques for measuring intracellular Ca 2+ transients 
have not been developed in vivo. The concentration f myo- 
cardial Ca 2+ was not measured at the end of reperfusion 
because cytosolic Ca 2~ is not elevated after reperfusion i  
models of reversible postischemic ontractile dysfunction 
(48,49). 
Amiloride may also be a scavenger of oxygen-derived free 
radicals and inhibits Na+/K + ATPase and protein kinases in 
millimolar concentrations (%10,50-52). These mechanisms 
were not investigated. Scavengers of oxygen free radicals 
improve postischemic function, but no study has demonstrated 
complete recovery within 2 h (2). Inhibitors of Na+/K + 
ATPase may exacerbate reperfusion i jury (53). The role of 
inhibition of protein kinases is unknown. 
Only one dose of nifedipine, sodium nitroprusside and 
hexamethylene amiloride was studied. Preliminary dose- 
response study-validated doses with the desired effects were 
infused. The 60-~tg/min dose of hexamethylene amiloride was 
the maximal dose inhibiting NaVH + exchange without the 
nonspecific effects of reduced heart rate and increased con- 
traction. 
Plasma concentrations of the drugs were not measured in
the present study. Despite this limitation, the minimal protein 
binding of these agents and the intracoronary infusion protocol 
permitted accurate stimation ofconcentrations on the basis of 
coronary and myocardial blood flow. 
Defibrillation may cause myocardial injury but did not 
affect he present data (54). Loss of function due to refractory 
ventricular fibrillation was similar to that in control dogs for all 
groups. Defibrillation was most common in high dose 
amiloride-treated dogs, but recovery of function was greatest. 
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Conclusions and clinical implications. Intracoronary infu- 
sion of amiloridc in doses 200 to 1,000 times greater than 
currently used to induce potassium-sparing natriuresis (55) 
prevented the contractile dysfunction of stunned myocardium 
but not ventricular arrhythmias. The multiple vascular and 
hemodynamic effects, including positive inotropic actions, re- 
duction in heart rate and vasodilation, did not account for the 
improved postischemic function. Inhibition of Na+/I-I * ex- 
change or L-type Ca 2+ channels alone also did not account for 
the improved function. The myocardial effect that may account 
for the prevention of contractile dysfunction by amiloride is 
inhibition of Na+/Ca 2+ exchange. Further research is needed 
to develop specific inhibitors of Na +/Ca 2+ exchange and define 
their direct effects on stunned myocardium, reperfusion injury 
and arrhythmias. 
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